Trial Search Results
Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
The purpose of this study is first, to determine whether baseline perfusion characteristics of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to determine whether baseline perfusion characteristics in those patients with resectable pancreatic cancer correlate with immunohistologic markers of angiogenesis such as microvessel density and vascular endothelial growth factor (VEGF) expression.
Stanford is currently not accepting patients for this trial.
- Procedure: Stereotactic body radiotherapy
- Drug: Iodixanol
- Drug: Iohexol
1. suspected and/or biopsy-proven pancreatic adenocarcinoma, and
2. referral to Radiology for pre-treatment baseline pancreatic protocol CT.
1) are absolute contraindications to intravenous iodinated contrast or CT scan.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study